We found that B2M was among the most significantly downregulated genes in B2MMUT cancers (two-sided limma-voom-based regression, P = 3.5 × 10−4, Benjamini–Hochberg false-discovery rate (FDR)-adjusted P = 0.12, adjusted for tumour type; Fig. 1d). This evidence concerns the gene B2M and cancer.